Arkolith/Insider Trading/RPRX/Form 4

Urist Marshall

EVP, Research & InvestmentsRoyalty Pharma plc (RPRX) · full profile →Form 4 · filed Nov 7, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 7, 2025Conversion(C)160K—$0207K
Nov 5, 2025Grant(A)5K—$044K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 7, 2025Conversion(C)16K—$0247K

Transaction Codes

C
Conversion of a derivative
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001838139-25-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML